A randomized, placebo-controlled clinical trial to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics and exploratory clinical activity of NM26-2198 in healthy subjects and in patients with moderate-to-severe atopic dermatitis (AD)

2023-503577-38-00 Protocol NB-NM026-2198-101 Human pharmacology (Phase I) - First administration to humans Ended

Start 7 Dec 2023 · End 2 Oct 2024 · Status Ended · 2 EU/EEA countries · 9 sites · Protocol NB-NM026-2198-101

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 156
Countries 2
Sites 9

Atopic Dermatitis

Key facts

Sponsor
Yellow Jersey Therapeutics AG
Participant type
Patients, Healthy volunteers
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Skin and Connective Tissue Diseases [C17]
Trial duration
7 Dec 2023 → 2 Oct 2024
Decision date (initial)
2023-09-15
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2023-503577-38-00
ClinicalTrials.gov
NCT05859724

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Atopic Dermatitis

VersionLevelCodeTermSystem organ class
21.1 LLT 10003639 Atopic dermatitis 10040785

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Yellow Jersey Therapeutics AG

Sponsor organisation
Yellow Jersey Therapeutics AG
Address
Gubelstrasse 34
City
Zug
Postcode
6300
Country
Switzerland

Scientific contact point

Organisation
Yellow Jersey Therapeutics AG
Contact name
Yellow Jersey Therapeutics Clinical Trials

Public contact point

Organisation
Yellow Jersey Therapeutics AG
Contact name
Yellow Jersey Therapeutics Clinical Trials

Locations

2 EU/EEA countries · 9 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ended 6 5
Poland Ended 8 4
Rest of world
Canada, United States
142

Investigational sites

Germany

5 sites · Ended
Universitaetsklinikum Bonn AöR
#4905:Klinik und Poliklinik für Dermatologie und Allergologie Klinisches Studienzentrum Dermatologie, Venusberg-Campus 1, Venusberg, Bonn
Technische Universitat Dresden
#4901:Dermatology, Venereology & Allergologie, Fetscherstrasse 74, Johannstadt-Nord, Dresden
University Medical Centre Schleswig-Holstein
#4904:Institut für Entzündungsmedizin, Ratzeburger Allee 160, 23538, Lübeck
Universitaetsmedizin Der Johannes Gutenberg-Universitaet Mainz
#4903:Dermatology, Langenbeckstrasse 1, Oberstadt, Mainz
Universitaetsklinikum Frankfurt AöR
#4902:Dermatology, Venereology & Allergologie, Theodor-Stern-Kai 7, 60590, Frankfurt Am Main

Poland

4 sites · Ended
Klinika Ambroziak Sp. z o.o.
#4801: NA, Ul. Ulica Kosiarzy 9a, 02-953, Warsaw
Copernicus Podmiot Leczniczy Sp. z o.o.
#4804:Oddzial Dermatologii, Al. Jana Pawla II 50, 80-462, Gdansk
Uniwersytecki Szpital Kliniczny Im. Fryderyka Chopina W Rzeszowie
#4802:Klinika Dermatologii, Ul. Fryderyka Szopena 2, 35-055, Rzeszow
Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych I Administracji
#4803:Klinika Dermatologii, Ul. Woloska 137, 02-507, Warsaw

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2023-12-07 2024-06-04 2024-07-15
Poland 2023-12-12 2024-01-29 2024-05-14

Application history

5 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-05-22 Germany Acceptable
2023-09-11
2023-09-15
2 SUBSTANTIAL MODIFICATION SM-1 2023-09-27 Germany Acceptable
2023-11-13
2023-11-15
3 SUBSTANTIAL MODIFICATION SM-3 2024-02-02 Germany Acceptable
2024-03-18
2024-03-22
4 SUBSTANTIAL MODIFICATION SM-5 2024-10-11 Germany Acceptable
2024-11-25
2024-11-29
5 NON SUBSTANTIAL MODIFICATION NSM-1 2024-12-05 Germany Acceptable
2024-11-25
2024-12-05